Paroxetine

Generic name: Pronounced as (pa rox' e teen)
Brand names
  • Brisdelle®
  • Paxil®
  • Paxil® CR
  • Pexeva®
Click on drug name to hear pronunciation

Medical Content Reviewed By HelloPharmacist Staff

Last Revised - 01/15/2022

A small number of children, teenagers, and young adults (up to 24 years of age) who took antidepressants ('mood elevators') such as paroxetine during clinical studies became suicidal (thinking about harming or killing oneself or planning or trying to do so). Children, teenagers, and young adults who take antidepressants to treat depression or other mental illnesses may be more likely to become suicidal than children, teenagers, and young adults who do not take antidepressants to treat these conditions. However, there are also risks when depression is not treated in children and teenagers. Talk to your child's doctor about these risks and whether your child should take an antidepressant, Children younger than 18 years of age should not normally take paroxetine, but in some cases, a doctor may decide that paroxetine is the best medication to treat a child's condition.

You should know that your mental health may change in unexpected ways when you take paroxetine or other antidepressants to treat depression or other mental illness even if you are an adult over 24 years of age. You may also experience changes in your mental health if you are a woman taking a low dose of paroxetine to treat hot flashes and you have never had depression or another mental illness. You may become suicidal, especially at the beginning of your treatment and any time that your dose is increased or decreased. You, your family, or your caregiver should call your doctor right away if you experience any of the following symptoms: new or worsening depression; thinking about harming or killing yourself, or planning or trying to do so; extreme worry; agitation; panic attacks; difficulty falling asleep or staying asleep; aggressive behavior; irritability; acting without thinking; severe restlessness; and frenzied abnormal excitement. Be sure that your family or caregiver knows which symptoms may be serious so they can call the doctor if you are unable to seek treatment on your own.

Your healthcare provider will want to see you often while you are taking paroxetine, especially at the beginning of your treatment. Be sure to keep all appointments for office visits with your doctor.

The doctor or pharmacist will give you the manufacturer's patient information sheet (Medication Guide) when you begin treatment with paroxetine. Read the information carefully and ask your doctor or pharmacist if you have any questions. You can also obtain the Medication Guide from the FDA website: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/UCM096273.

No matter what your age, before you take an antidepressant, you, your parent, or your caregiver should talk to your doctor about the risks and benefits of treating your condition with an antidepressant or with other treatments. You should also talk about the risks and benefits of not treating your condition. You should know that having depression or another mental illness greatly increases the risk that you will become suicidal. This risk is higher if you or anyone in your family has or has ever had bipolar disorder (mood that changes from depressed to abnormally excited) or mania (frenzied, abnormally excited mood) or has thought about or attempted suicide. Talk to your doctor about your condition, symptoms, and personal and family medical history. You and your doctor will decide what type of treatment is right for you.

Paroxetine tablets, suspension (liquid), and extended-release (long-acting) tablets are used to treat depression, panic disorder (sudden, unexpected attacks of extreme fear and worry about these attacks), and social anxiety disorder (extreme fear of interacting with others or performing in front of others that interferes with normal life). Paroxetine tablets and suspension are also used to treat obsessive-compulsive disorder (bothersome thoughts that won't go away and the need to perform certain actions over and over), generalized anxiety disorder (GAD; excessive worrying that is difficult to control), and posttraumatic stress disorder (disturbing psychological symptoms that develop after a frightening experience). Paroxetine extended-release tablets are also used to treat premenstrual dysphoric disorder (PMDD, physical and psychological symptoms that occur before the onset of the menstrual period each month). Paroxetine capsules (Brisdelle) are used to treat hot flashes (sudden feelings of warmth, especially in the face, neck, and chest) in women who are experiencing menopause (stage of life when menstrual periods become less frequent and stop and women may experience other symptoms and body changes). Paroxetine is in a class of medications called selective serotonin-reuptake inhibitors (SSRIs). It treats depression and other mental illnesses by increasing the amount of serotonin, a natural substance in the brain that helps maintain mental balance. There is not enough information available at this time to know how paroxetine works to treat hot flashes.

Paroxetine comes as a tablet, a suspension (liquid), a controlled-release (long-acting) tablet, and a capsule to take by mouth. The tablets, suspension, and controlled-release tablets are usually taken once daily in the morning or evening, with or without food. The capsules are usually taken once a day at bedtime with or without food. You may want to take paroxetine with food to prevent stomach upset. Take paroxetine at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take paroxetine exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.

Shake the liquid well before each use to mix the medication evenly.

Swallow the extended-release and regular tablets whole; do not chew or crush them.

If you are taking paroxetine tablets, suspension, or controlled-release tablets, your doctor may start you on a low dose of paroxetine and gradually increase your dose, not more than once a week.

Paroxetine capsules contain a lower dose of paroxetine than is needed to treat depression and other forms of mental illness. Do not take paroxetine capsules to treat a mental illness. If you think you have depression or another mental illness, talk to your doctor about treatment.

Paroxetine may help control your symptoms but will not cure your condition. It may take several weeks or longer before you feel the full benefit of paroxetine. Continue to take paroxetine even if you feel well. Do not stop taking paroxetine without talking to your doctor. Your doctor may decrease your dose gradually. If you suddenly stop taking paroxetine tablets, suspension, or controlled-release tablets, you may experience withdrawal symptoms such as depression; mood changes; frenzied or abnormally excited mood; irritability; anxiety; confusion; dizziness; headache; tiredness; numbness or tingling in the arms, legs, hands, or feet; unusual dreams; difficulty falling asleep or staying asleep; nausea; or sweating. Tell your doctor if you experience any of these symptoms when your dose of paroxetine is decreased.

Paroxetine is also sometimes used to treat chronic headaches, tingling, pain, or numbness in the hands and feet caused by diabetes, and certain male sexual problems. Paroxetine is also used with other medications to treat bipolar disorder (mood that changes from depressed to abnormally excited). Talk to your doctor about the possible risks of using this drug for your condition.

This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.

Before taking paroxetine,

  • tell your doctor and pharmacist if you are allergic to paroxetine, any other medications, or any of the ingredients in paroxetine tablets, controlled-release tablets, capsules, or suspension. Ask your pharmacist or check the Medication Guide for a list of the ingredients

  • tell your doctor if you are taking monoamine oxidase (MAO) inhibitors, including isocarboxazid (Marplan), linezolid (Zyvox), methylene blue, phenelzine (Nardil), selegiline (Emsam, Zelapar), and tranylcypromine (Parnate); if you have stopped taking them within the past 2 weeks; or if you are taking thioridazine or pimozide (Orap). Your doctor will probably tell you not to take paroxetine. If you stop taking paroxetine, you should wait at least 2 weeks before you start to take an MAO inhibitor.

  • tell your doctor and pharmacist what other prescription and nonprescription medications and vitamins you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven) and heparin; antidepressants ('mood elevators') such as amitriptyline, amoxapine, clomipramine (Anafranil), desipramine (Norpramin), doxepin, imipramine (Tofranil), nortriptyline (Pamelor), protriptyline, and trimipramine; antihistamines; aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (Advil, Motrin), and naproxen (Aleve, Naprosyn); atomoxetine (Straterra); buspirone (Buspar); chlorpromazine (Thorazine); cimetidine (Tagamet); clopidogrel (Plavix); dextromethorphan (found in many cough medications; in Nuedexta); digoxin (Lanoxin); dipyridamole (Persantine); diuretics ('water pills'); fentanyl (Actiq, Fentora, Lazanda, others); fosamprenavir (Lexiva); haloperidol (Haldol); isoniazid (INH, Nydrazid); lithium (Lithobid); medications for irregular heartbeat such as flecainide or propafenone (Rythmol); medications for mental illness and nausea; medications for migraine headaches such as almotriptan, eletriptan (Relpax), frovatriptan (Frova), naratriptan (Amerge), rizatriptan (Maxalt), sumatriptan (Imitrex), and zolmitriptan (Zomig); medications for seizures such as phenobarbital and phenytoin (Dilantin);metoprolol (Lopressor, Toprol XL); other selective serotonin-reuptake inhibitors such as citalopram (Celexa), fluoxetine (Prozac), fluvoxamine (Luvox), and sertraline (Zoloft); propranolol (Inderal); risperidone (Risperdal); ritonavir (Norvir); serotonin–norepinephrine reuptake inhibitors (SNRI) medications such as desvenlafaxine (Khedezla, Pristiq), duloxetine (Cymbalta), levomilnacipran (Fetzima), and venlafaxine; tamoxifen (Soltamox); theophylline (Theobid, Theo-Dur); tramadol (Conzip, Qdolo,Ultram, in Ultracet); and trazodone. Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with paroxetine, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.

  • you should know that paroxetine products that have different brand names are available and are used to treat different conditions. Do not take more than one product that contains paroxetine at a time.

  • tell your doctor what herbal products and nutritional supplements you are taking, especially St. John's wort and tryptophan.

  • tell your doctor if you use or have ever used street drugs or have overused prescription medications, if you have recently had a heart attack, and if you have a low level of sodium in your blood. Also tell your doctor if you have or have ever had seizures; glaucoma; bleeding problems; bone problems including osteoporosis (a condition in which the bones become thin and weak and break easily) or bone fractures; or liver, kidney, or heart disease.

  • tell your doctor if you are pregnant, if you plan to become pregnant, or if you are breastfeeding. If you become pregnant while taking paroxetine, call your doctor immediately. Paroxetine may cause heart defects in the fetus if it is taken during early pregnancy and problems in newborns following delivery if it is taken during the last months of pregnancy.

  • talk to your doctor about the risks and benefits of taking paroxetine if you are 65 years of age or older. Older adults should not usually take paroxetine because it is not as safe or effective as other medications that can be used to treat the same condition.

  • if you are having surgery, including dental surgery tell the doctor or dentist that you are taking paroxetine.

  • you should know that paroxetine may make you drowsy and affect your judgment and thinking. Do not drive a car or operate machinery until you know how this medication affects you.

  • ask your doctor about the safe use of alcoholic beverages while you are taking paroxetine.

  • you should know that paroxetine may cause angle-closure glaucoma (a condition where the fluid is suddenly blocked and unable to flow out of the eye causing a quick, severe increase in eye pressure which may lead to a loss of vision). Talk to your doctor about having an eye examination before you start taking this medication. If you have nausea, eye pain, changes in vision, such as seeing colored rings around lights, and swelling or redness in or around the eye, call your doctor or get emergency medical treatment right away.

Unless your doctor tells you otherwise, continue your normal diet.

Take the missed dose as soon as you remember it. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.

  • Paroxetine may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

    • headache

    • dizziness

    • weakness

    • difficulty concentrating

    • nervousness

    • forgetfulness

    • confusion

    • sleepiness

    • nausea

    • vomiting

    • diarrhea

    • constipation

    • gas

    • stomach pain

    • heartburn

    • changes in ability to taste food

    • decreased appetite

    • weight loss or gain

    • sexual problems in males; decreased sex drive, inability to get or keep an erection, or delayed or absent ejaculation

    • sexual problems in females; decreased sex drive, or delayed orgasm or unable to have an orgasm

    • dry mouth

    • sweating

    • yawning

    • pain in the back, muscles, bones, or anywhere in the body

    • tenderness or swelling of joints

  • Some side effects can be serious. If you experience any of the following symptoms or those listed in the IMPORTANT WARNING or SPECIAL PRECAUTIONS sections, call your doctor immediately or get emergency medical treatment:

    • seeing things or hearing voices that do not exist (hallucinating)

    • fainting

    • rapid, pounding, or irregular heartbeat

    • chest pain

    • difficulty breathing

    • seizures

    • agitation, fever, sweating, confusion, fast or irregular heartbeat, and severe muscle stiffness or twitching, hallucinations, loss of coordination, nausea, vomiting, or diarrhea

    • abnormal bleeding or bruising

    • tiny red spots directly under the skin

    • peeling or blistering of skin

    • sore throat, fever, chills, cough, and other signs of infection

    • uncontrollable shaking of a part of the body

    • unsteady walking that may cause falling

    • numbness or tingling in your hands, feet, arms, or legs

    • painful erection that lasts for hours

    • sudden nausea, vomiting, weakness, cramping, bloating, swelling, tightness in hands and feet, dizziness, headache and/or confusion

    • hives

    • rash

    • itching

    • swelling of the face, throat, tongue, lips, eyes, hands, feet, ankles, or lower legs

    • hoarseness

    • black and tarry stools

    • red blood in stools

    • bloody vomit

    • vomit that looks like coffee grounds

    • bone pain or fracture

    • tenderness, swelling, or bruising of one part of your body

  • Paroxetine may decrease appetite and cause weight loss in children. Your child's doctor will watch his or her growth carefully. Talk to your child's doctor if you have concerns about your child's growth or weight while he or she is taking this medication. Talk to your child's doctor about the risks of giving paroxetine to your child.

  • Paroxetine may cause other side effects. Call your doctor if you have any unusual problems while taking this medication.

  • If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) MedWatch Adverse Event Reporting program online (http://www.fda.gov/Safety/MedWatch) or by phone (1-800-332-1088).

Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat and moisture (not in the bathroom).

It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. http://www.upandaway.org

Unneeded medications should be disposed of in special ways to ensure that pets, children, and other people cannot consume them. However, you should not flush this medication down the toilet. Instead, the best way to dispose of your medication is through a medicine take-back program. Talk to your pharmacist or contact your local garbage/recycling department to learn about take-back programs in your community. See the FDA's Safe Disposal of Medicines website (http://goo.gl/c4Rm4p) for more information if you do not have access to a take-back program.

In case of overdose, call the poison control helpline at 1-800-222-1222. Information is also available online at https://www.poisonhelp.org/help. If the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, immediately call emergency services at 911.

Symptoms of overdose may include the following:

  • drowsiness

  • coma

  • seizures

  • fever, sweating, confusion, fast or irregular heartbeat, and severe muscle stiffness or twitching

  • nausea, vomiting, diarrhea

  • aggressive behavior

  • dark red or brown urine

  • frenzied, abnormally excited mood

Keep all appointments with your doctor.

Before having any laboratory test (especially those that involve methylene blue), tell your doctor and the laboratory personnel that you are taking paroxetine.

Do not let anyone else take your medication. Ask your pharmacist any questions you have about refilling your prescription.

It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.

Drug Interaction
Moxifloxacin Moxifloxacin The metabolism of Paroxetine can be decreased when combined with Moxifloxacin.
Repaglinide Repaglinide The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Repaglinide.
Montelukast Montelukast The metabolism of Montelukast can be decreased when combined with Paroxetine.
Insulin Glargine (rDNA origin) Injection Insulin Glargine (rDNA origin) Injection The metabolism of Paroxetine can be increased when combined with Insulin glargine.
Delavirdine Delavirdine The metabolism of Paroxetine can be decreased when combined with Delavirdine.
Nevirapine Nevirapine The metabolism of Nevirapine can be decreased when combined with Paroxetine.
Atorvastatin Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Paroxetine.
Dolasetron Dolasetron The metabolism of Dolasetron can be decreased when combined with Paroxetine.
Aminophylline Aminophylline The metabolism of Aminophylline can be decreased when combined with Paroxetine.
Anagrelide Anagrelide The risk or severity of hemorrhage can be increased when Paroxetine is combined with Anagrelide.
Bisacodyl Bisacodyl The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Paroxetine.
Candesartan Candesartan The metabolism of Candesartan can be decreased when combined with Paroxetine.
Cilostazol Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Paroxetine.
Clopidogrel Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Paroxetine.
Diphenoxylate Diphenoxylate The risk or severity of serotonin syndrome can be increased when Diphenoxylate is combined with Paroxetine.
Estrogen and Progestin (Oral Contraceptives) Estrogen and Progestin (Oral Contraceptives) The metabolism of Paroxetine can be decreased when combined with Conjugated estrogens.
Fenofibrate Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Paroxetine.
Guanfacine Guanfacine The risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.
Magnesium Hydroxide Magnesium Hydroxide The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Paroxetine.
Magnesium Oxide Magnesium Oxide The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Paroxetine.
Miglitol Miglitol The risk or severity of hypoglycemia can be increased when Miglitol is combined with Paroxetine.
Naratriptan Naratriptan The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Naratriptan.
Olsalazine Olsalazine The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Olsalazine.
Paregoric Paregoric The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Morphine.
Penbutolol Penbutolol The metabolism of Acebutolol can be decreased when combined with Paroxetine.
Pentazocine Pentazocine The risk or severity of serotonin syndrome can be increased when Pentazocine is combined with Paroxetine.
Polyethylene glycol-electrolyte solution (PEG-ES) Polyethylene glycol-electrolyte solution (PEG-ES) The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Paroxetine.
Psyllium Psyllium The therapeutic efficacy of Plantago seed can be decreased when used in combination with Paroxetine.
Ranitidine Ranitidine The metabolism of Ranitidine can be decreased when combined with Paroxetine.
Reserpine Reserpine The risk or severity of adverse effects can be increased when Reserpine is combined with Paroxetine.
Rizatriptan Rizatriptan The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Rizatriptan.
Sumatriptan Sumatriptan The risk or severity of adverse effects can be increased when Sumatriptan is combined with Paroxetine.
Tacrolimus Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Paroxetine.
Tizanidine Tizanidine The risk or severity of adverse effects can be increased when Paroxetine is combined with Tizanidine.
Zolmitriptan Zolmitriptan The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Zolmitriptan.
Famotidine Injection Famotidine Injection The metabolism of Paroxetine can be decreased when combined with Famotidine.
Fluconazole Injection Fluconazole Injection The metabolism of Paroxetine can be decreased when combined with Fluconazole.
Hydromorphone Injection Hydromorphone Injection The risk or severity of serotonin syndrome can be increased when Hydromorphone is combined with Paroxetine.
Interferon Beta-1b Injection Interferon Beta-1b Injection The metabolism of Paroxetine can be decreased when combined with Interferon beta-1b.
Interferon Gamma-1b Injection Interferon Gamma-1b Injection The metabolism of Paroxetine can be decreased when combined with Interferon gamma-1b.
Levofloxacin Injection Levofloxacin Injection The metabolism of Paroxetine can be decreased when combined with Levofloxacin.
Meperidine Injection Meperidine Injection The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Meperidine.
Metoclopramide Injection Metoclopramide Injection The risk or severity of sedation can be increased when Metoclopramide is combined with Paroxetine.
Morphine Injection Morphine Injection The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Morphine.
Zidovudine Injection Zidovudine Injection The metabolism of Zidovudine can be decreased when combined with Paroxetine.
Altretamine Altretamine Paroxetine may increase the serotonergic activities of Amphetamine.
Cyclosporine Cyclosporine The metabolism of Cyclosporine can be decreased when combined with Paroxetine.
Ondansetron Ondansetron The metabolism of Ondansetron can be decreased when combined with Paroxetine.
Enoxaparin Injection Enoxaparin Injection The risk or severity of hemorrhage can be increased when Paroxetine is combined with Enoxaparin.
Granisetron Granisetron The risk or severity of adverse effects can be increased when Granisetron is combined with Paroxetine.
Torsemide Torsemide The metabolism of Paroxetine can be decreased when combined with Torasemide.
Olanzapine Olanzapine The metabolism of Paroxetine can be decreased when combined with Olanzapine.
Alosetron Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Paroxetine.
Dofetilide Dofetilide The metabolism of Dofetilide can be decreased when combined with Paroxetine.
Entacapone Entacapone The risk or severity of adverse effects can be increased when Entacapone is combined with Paroxetine.
Hydroxychloroquine Hydroxychloroquine The metabolism of Paroxetine can be decreased when combined with Hydroxychloroquine.
Meloxicam Meloxicam The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Meloxicam.
Oxcarbazepine Oxcarbazepine The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Paroxetine.
Pantoprazole Pantoprazole The metabolism of Paroxetine can be decreased when combined with Pantoprazole.
Telmisartan Telmisartan The metabolism of Paroxetine can be decreased when combined with Telmisartan.
Zaleplon Zaleplon The risk or severity of adverse effects can be increased when Zaleplon is combined with Paroxetine.
Anakinra Anakinra The metabolism of Paroxetine can be increased when combined with Anakinra.
Desloratadine Desloratadine The risk or severity of adverse effects can be increased when Paroxetine is combined with Desloratadine.
Linezolid Linezolid The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Paroxetine.
Pentosan Polysulfate Pentosan Polysulfate The risk or severity of hemorrhage can be increased when Paroxetine is combined with Pentosan polysulfate.
Rivastigmine Rivastigmine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Rivastigmine.
Trimipramine Trimipramine The metabolism of Paroxetine can be decreased when combined with Trimipramine.
Etanercept Injection Etanercept Injection The metabolism of Paroxetine can be increased when combined with Etanercept.
Glycopyrrolate Glycopyrrolate The risk or severity of adverse effects can be increased when Paroxetine is combined with Glycopyrronium.
Modafinil Modafinil The metabolism of Paroxetine can be decreased when combined with Armodafinil.
Tenofovir Tenofovir The metabolism of Tenofovir can be decreased when combined with Paroxetine.
Choline Magnesium Trisalicylate Choline Magnesium Trisalicylate The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Choline magnesium trisalicylate.
Sirolimus Sirolimus The metabolism of Sirolimus can be decreased when combined with Paroxetine.
Epinephrine Injection Epinephrine Injection The risk or severity of Tachycardia can be increased when Epinephrine is combined with Paroxetine.
Escitalopram Escitalopram The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Escitalopram.
Zonisamide Zonisamide The risk or severity of adverse effects can be increased when Zonisamide is combined with Paroxetine.
Adalimumab Injection Adalimumab Injection The metabolism of Paroxetine can be increased when combined with Adalimumab.
Aripiprazole Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Paroxetine.
Atomoxetine Atomoxetine The metabolism of Atomoxetine can be decreased when combined with Paroxetine.
Dexmethylphenidate Dexmethylphenidate The risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Paroxetine.
Teriparatide Injection Teriparatide Injection The therapeutic efficacy of Teriparatide can be decreased when used in combination with Paroxetine.
Atazanavir Atazanavir The metabolism of Atazanavir can be decreased when combined with Paroxetine.
Almotriptan Almotriptan The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Almotriptan.
Eletriptan Eletriptan The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Eletriptan.
Mefloquine Mefloquine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Mefloquine.
Polyethylene Glycol 3350 Polyethylene Glycol 3350 The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Paroxetine.
Rosuvastatin Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Paroxetine.
Vardenafil Vardenafil The metabolism of Vardenafil can be decreased when combined with Paroxetine.
Alfuzosin Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Paroxetine.
Aprepitant Aprepitant The metabolism of Paroxetine can be decreased when combined with Aprepitant.
Interferon Beta-1a Subcutaneous Injection Interferon Beta-1a Subcutaneous Injection The metabolism of Paroxetine can be decreased when combined with Interferon beta-1a.
Memantine Memantine The metabolism of Paroxetine can be decreased when combined with Memantine.
Tegaserod Tegaserod The metabolism of Tegaserod can be decreased when combined with Paroxetine.
Fosamprenavir Fosamprenavir The serum concentration of Paroxetine can be decreased when it is combined with Fosamprenavir.
Frovatriptan Frovatriptan The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Frovatriptan.
Gemifloxacin Gemifloxacin The metabolism of Paroxetine can be decreased when combined with Gemifloxacin.
Progesterone Progesterone The metabolism of Progesterone can be decreased when combined with Paroxetine.
Apomorphine Injection Apomorphine Injection The risk or severity of adverse effects can be increased when Apomorphine is combined with Paroxetine.
Infliximab Injection Infliximab Injection The metabolism of Paroxetine can be increased when combined with Infliximab.
Protriptyline Protriptyline The metabolism of Paroxetine can be decreased when combined with Protriptyline.
Rifaximin Rifaximin The metabolism of Paroxetine can be increased when combined with Rifaximin.
Duloxetine Duloxetine The metabolism of Paroxetine can be decreased when combined with Duloxetine.
Norethindrone Norethindrone The metabolism of Norethisterone can be decreased when combined with Paroxetine.
Trospium Trospium Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Trospium.
Bosentan Bosentan The metabolism of Bosentan can be decreased when combined with Paroxetine.
Cinacalcet Cinacalcet The metabolism of Paroxetine can be decreased when combined with Cinacalcet.
Erlotinib Erlotinib The metabolism of Erlotinib can be decreased when combined with Paroxetine.
Eszopiclone Eszopiclone The risk or severity of CNS depression can be increased when Paroxetine is combined with Eszopiclone.
Insulin Aspart (rDNA Origin) Injection Insulin Aspart (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin aspart.
Solifenacin Solifenacin The metabolism of Solifenacin can be decreased when combined with Paroxetine.
Voriconazole Voriconazole The metabolism of Paroxetine can be decreased when combined with Voriconazole.
Dextroamphetamine Dextroamphetamine Paroxetine may increase the serotonergic activities of Amphetamine.
Entecavir Entecavir The metabolism of Paroxetine can be decreased when combined with Entecavir.
Peginterferon Alfa-2a Injection Peginterferon Alfa-2a Injection The metabolism of Paroxetine can be decreased when combined with Peginterferon alfa-2a.
Peginterferon Alfa-2b (PEG-Intron) Peginterferon Alfa-2b (PEG-Intron) The serum concentration of Paroxetine can be increased when it is combined with Peginterferon alfa-2b.
Pramlintide Injection Pramlintide Injection The risk or severity of reduced gastrointestinal motility can be increased when Pramlintide is combined with Paroxetine.
Sodium Oxybate Sodium Oxybate Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Exenatide Injection Exenatide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Exenatide.
Isocarboxazid Isocarboxazid Paroxetine may increase the serotonergic activities of Isocarboxazid.
Ramelteon Ramelteon The risk or severity of adverse effects can be increased when Ramelteon is combined with Paroxetine.
Darifenacin Darifenacin The metabolism of Darifenacin can be decreased when combined with Paroxetine.
Fentanyl Fentanyl The metabolism of Fentanyl can be decreased when combined with Paroxetine.
Pregabalin Pregabalin The therapeutic efficacy of Paroxetine can be increased when used in combination with Pregabalin.
Deferasirox Deferasirox The serum concentration of Paroxetine can be increased when it is combined with Deferasirox.
Phenylephrine Phenylephrine The metabolism of Paroxetine can be increased when combined with Phenylephrine.
Tipranavir Tipranavir The metabolism of Tipranavir can be decreased when combined with Paroxetine.
Felbamate Felbamate The risk or severity of adverse effects can be increased when Felbamate is combined with Paroxetine.
Insulin Detemir (rDNA Origin) Injection Insulin Detemir (rDNA Origin) Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Insulin detemir.
Ranolazine Ranolazine The serum concentration of Ranolazine can be increased when it is combined with Paroxetine.
Abatacept Injection Abatacept Injection The metabolism of Paroxetine can be increased when combined with Abatacept.
Rasagiline Rasagiline Rasagiline may increase the serotonergic activities of Paroxetine.
Imatinib Imatinib The metabolism of Imatinib can be decreased when combined with Paroxetine.
Sitagliptin Sitagliptin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Sitagliptin.
Gefitinib Gefitinib The metabolism of Gefitinib can be decreased when combined with Paroxetine.
Albuterol Albuterol The risk or severity of Tachycardia can be increased when Paroxetine is combined with Salbutamol.
Paliperidone Paliperidone The metabolism of Paliperidone can be decreased when combined with Paroxetine.
Bortezomib Bortezomib The metabolism of Bortezomib can be decreased when combined with Paroxetine.
Insulin Glulisine (rDNA origin) Injection Insulin Glulisine (rDNA origin) Injection The metabolism of Paroxetine can be increased when combined with Insulin glulisine.
Lubiprostone Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Paroxetine.
Primaquine Primaquine The metabolism of Paroxetine can be decreased when combined with Primaquine.
Darunavir Darunavir The serum concentration of Paroxetine can be decreased when it is combined with Darunavir.
Pemetrexed Injection Pemetrexed Injection The metabolism of Paroxetine can be decreased when combined with Pemetrexed.
Dimenhydrinate Dimenhydrinate The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Paroxetine.
Lisdexamfetamine Lisdexamfetamine The metabolism of Lisdexamfetamine can be decreased when combined with Paroxetine.
Nabilone Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Retapamulin Retapamulin The metabolism of Retapamulin can be decreased when combined with Paroxetine.
Sorafenib Sorafenib The metabolism of Paroxetine can be decreased when combined with Sorafenib.
Sunitinib Sunitinib The metabolism of Sunitinib can be decreased when combined with Paroxetine.
Dronabinol Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Lapatinib Lapatinib The metabolism of Lapatinib can be decreased when combined with Paroxetine.
Levocetirizine Levocetirizine The risk or severity of adverse effects can be increased when Levocetirizine is combined with Paroxetine.
Dasatinib Dasatinib The metabolism of Dasatinib can be decreased when combined with Paroxetine.
Mexiletine Mexiletine The metabolism of Mexiletine can be decreased when combined with Paroxetine.
Armodafinil Armodafinil The metabolism of Paroxetine can be decreased when combined with Armodafinil.
Paclitaxel (with polyoxyethylated castor oil) Injection Paclitaxel (with polyoxyethylated castor oil) Injection The therapeutic efficacy of Castor oil can be decreased when used in combination with Paroxetine.
Temsirolimus Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Paroxetine.
Nilotinib Nilotinib The metabolism of Nilotinib can be decreased when combined with Paroxetine.
Bexarotene Bexarotene The metabolism of Bexarotene can be decreased when combined with Paroxetine.
Chloramphenicol Injection Chloramphenicol Injection The metabolism of Paroxetine can be decreased when combined with Chloramphenicol.
Desmopressin Desmopressin The risk or severity of hyponatremia can be increased when Paroxetine is combined with Desmopressin.
Betaine Betaine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Glycine betaine.
OnabotulinumtoxinA Injection OnabotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type A.
RimabotulinumtoxinB Injection RimabotulinumtoxinB Injection The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum Toxin Type B.
Etravirine Etravirine The metabolism of Etravirine can be decreased when combined with Paroxetine.
Desvenlafaxine Desvenlafaxine The risk or severity of adverse effects can be increased when Paroxetine is combined with Desvenlafaxine.
Cevimeline Cevimeline The metabolism of Cevimeline can be decreased when combined with Paroxetine.
Nebivolol Nebivolol The metabolism of Nebivolol can be decreased when combined with Paroxetine.
Tretinoin Tretinoin The metabolism of Tretinoin can be decreased when combined with Paroxetine.
Bendamustine Injection Bendamustine Injection The metabolism of Bendamustine can be decreased when combined with Paroxetine.
Flecainide Flecainide The metabolism of Flecainide can be decreased when combined with Paroxetine.
Certolizumab Injection Certolizumab Injection The metabolism of Paroxetine can be increased when combined with Certolizumab pegol.
Ixabepilone Injection Ixabepilone Injection The metabolism of Ixabepilone can be decreased when combined with Paroxetine.
Irinotecan Injection Irinotecan Injection The metabolism of Irinotecan can be decreased when combined with Paroxetine.
Praziquantel Praziquantel The metabolism of Praziquantel can be decreased when combined with Paroxetine.
Rufinamide Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Paroxetine.
Midazolam Midazolam The serum concentration of Midazolam can be increased when it is combined with Paroxetine.
Naltrexone Injection Naltrexone Injection The risk or severity of adverse effects can be increased when Naltrexone is combined with Paroxetine.
Eltrombopag Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Paroxetine.
Milnacipran Milnacipran The risk or severity of adverse effects can be increased when Paroxetine is combined with Milnacipran.
Dexlansoprazole Dexlansoprazole The metabolism of Paroxetine can be decreased when combined with Dexlansoprazole.
Sodium Phosphate Sodium Phosphate The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Paroxetine.
Fesoterodine Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Paroxetine.
Betaxolol Betaxolol The metabolism of Betaxolol can be decreased when combined with Paroxetine.
Iloperidone Iloperidone The metabolism of Iloperidone can be decreased when combined with Paroxetine.
Prasugrel Prasugrel The risk or severity of hemorrhage can be increased when Paroxetine is combined with Prasugrel.
Lacosamide Lacosamide The risk or severity of adverse effects can be increased when Lacosamide is combined with Paroxetine.
Everolimus Everolimus The metabolism of Everolimus can be decreased when combined with Paroxetine.
Tolvaptan (low blood sodium) Tolvaptan (low blood sodium) The metabolism of Tolvaptan can be decreased when combined with Paroxetine.
Dronedarone Dronedarone The metabolism of Dronedarone can be decreased when combined with Paroxetine.
AbobotulinumtoxinA Injection AbobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type A.
Palonosetron Injection Palonosetron Injection The metabolism of Palonosetron can be decreased when combined with Paroxetine.
Saxagliptin Saxagliptin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Saxagliptin.
Romidepsin Injection Romidepsin Injection The metabolism of Romidepsin can be decreased when combined with Paroxetine.
Tapentadol Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Golimumab Injection Golimumab Injection The metabolism of Paroxetine can be increased when combined with Golimumab.
Pazopanib Pazopanib The metabolism of Pazopanib can be decreased when combined with Paroxetine.
Asenapine Asenapine The risk or severity of adverse effects can be increased when Paroxetine is combined with Asenapine.
Vigabatrin Vigabatrin The risk or severity of adverse effects can be increased when Vigabatrin is combined with Paroxetine.
Pitavastatin Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Paroxetine.
Albendazole Albendazole The metabolism of Albendazole can be decreased when combined with Paroxetine.
Oxymorphone Oxymorphone The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Oxymorphone.
Dabigatran Dabigatran The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dabigatran.
Liraglutide Injection Liraglutide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Liraglutide.
Tocilizumab Injection Tocilizumab Injection The metabolism of Paroxetine can be increased when combined with Tocilizumab.
IncobotulinumtoxinA Injection IncobotulinumtoxinA Injection The risk or severity of adverse effects can be increased when Paroxetine is combined with Botulinum toxin type A.
Cabazitaxel Injection Cabazitaxel Injection The metabolism of Cabazitaxel can be decreased when combined with Paroxetine.
Lurasidone Lurasidone The risk or severity of adverse effects can be increased when Lurasidone is combined with Paroxetine.
Acetaminophen Injection Acetaminophen Injection The metabolism of Acetaminophen can be decreased when combined with Paroxetine.
Vilazodone Vilazodone The metabolism of Vilazodone can be decreased when combined with Paroxetine.
Terbutaline Injection Terbutaline Injection The therapeutic efficacy of Paroxetine can be decreased when used in combination with Terbutaline.
Busulfan Injection Busulfan Injection The metabolism of Busulfan can be decreased when combined with Paroxetine.
Roflumilast Roflumilast The metabolism of Roflumilast can be decreased when combined with Paroxetine.
Linagliptin Linagliptin The metabolism of Linagliptin can be decreased when combined with Paroxetine.
Rilpivirine Rilpivirine The metabolism of Paroxetine can be decreased when combined with Rilpivirine.
Potassium Iodide Potassium Iodide The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Paroxetine.
Cyclophosphamide Injection Cyclophosphamide Injection The metabolism of Cyclophosphamide can be decreased when combined with Paroxetine.
Abiraterone Abiraterone The serum concentration of Paroxetine can be increased when it is combined with Abiraterone.
Rivaroxaban Rivaroxaban The risk or severity of hemorrhage can be increased when Paroxetine is combined with Rivaroxaban.
Ticagrelor Ticagrelor The risk or severity of hemorrhage can be increased when Paroxetine is combined with Ticagrelor.
Brentuximab Vedotin Injection Brentuximab Vedotin Injection The metabolism of Brentuximab vedotin can be decreased when combined with Paroxetine.
Ruxolitinib Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Paroxetine.
Vandetanib Vandetanib The metabolism of Vandetanib can be decreased when combined with Paroxetine.
Clobazam Clobazam The metabolism of Paroxetine can be decreased when combined with Clobazam.
Vemurafenib Vemurafenib The serum concentration of Paroxetine can be increased when it is combined with Vemurafenib.
Vismodegib Vismodegib The metabolism of Vismodegib can be decreased when combined with Paroxetine.
Axitinib Axitinib The metabolism of Axitinib can be decreased when combined with Paroxetine.
Crizotinib Crizotinib The metabolism of Crizotinib can be decreased when combined with Paroxetine.
Cabergoline Cabergoline The metabolism of Paroxetine can be decreased when combined with Cabergoline.
Fondaparinux Injection Fondaparinux Injection The risk or severity of hemorrhage can be increased when Paroxetine is combined with Fondaparinux.
Ezogabine Ezogabine The risk or severity of adverse effects can be increased when Tiagabine is combined with Paroxetine.
Iloprost Iloprost The risk or severity of hemorrhage can be increased when Paroxetine is combined with Iloprost.
Enzalutamide Enzalutamide The metabolism of Paroxetine can be increased when combined with Enzalutamide.
Mirabegron Mirabegron The risk or severity of urinary retention can be increased when Paroxetine is combined with Mirabegron.
Regorafenib Regorafenib The metabolism of Regorafenib can be decreased when combined with Paroxetine.
Bosutinib Bosutinib The metabolism of Bosutinib can be decreased when combined with Paroxetine.
Linaclotide Linaclotide The therapeutic efficacy of Linaclotide can be decreased when used in combination with Paroxetine.
Teriflunomide Teriflunomide The serum concentration of Paroxetine can be decreased when it is combined with Teriflunomide.
Lorcaserin Lorcaserin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Mecasermin.
Cabozantinib (thyroid cancer) Cabozantinib (thyroid cancer) The metabolism of Cabozantinib can be decreased when combined with Paroxetine.
Icosapent Ethyl Icosapent Ethyl The risk or severity of hemorrhage can be increased when Paroxetine is combined with Icosapent ethyl.
Tofacitinib Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Paroxetine.
Alogliptin Alogliptin The metabolism of Alogliptin can be decreased when combined with Paroxetine.
Ponatinib Ponatinib The metabolism of Ponatinib can be decreased when combined with Paroxetine.
Pomalidomide Pomalidomide The metabolism of Paroxetine can be decreased when combined with Pomalidomide.
Ado-trastuzumab Emtansine Injection Ado-trastuzumab Emtansine Injection The metabolism of Trastuzumab emtansine can be decreased when combined with Paroxetine.
Apixaban Apixaban The risk or severity of hemorrhage can be increased when Paroxetine is combined with Apixaban.
Canagliflozin Canagliflozin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Canagliflozin.
Dabrafenib Dabrafenib The serum concentration of Paroxetine can be decreased when it is combined with Dabrafenib.
Ospemifene Ospemifene The metabolism of Ospemifene can be decreased when combined with Paroxetine.
Levomilnacipran Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Paroxetine.
Vortioxetine Vortioxetine The metabolism of Vortioxetine can be decreased when combined with Paroxetine.
Perampanel Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Ibrutinib Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Paroxetine.
Lomitapide Lomitapide The metabolism of Lomitapide can be decreased when combined with Paroxetine.
Ketorolac Injection Ketorolac Injection The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ketorolac.
Simeprevir Simeprevir The metabolism of Paroxetine can be decreased when combined with Simeprevir.
Dapagliflozin Dapagliflozin The metabolism of Dapagliflozin can be decreased when combined with Paroxetine.
Apremilast Apremilast The metabolism of Paroxetine can be increased when combined with Apremilast.
Droxidopa Droxidopa The risk or severity of Tachycardia can be increased when Paroxetine is combined with Droxidopa.
Ceritinib Ceritinib The metabolism of Ceritinib can be decreased when combined with Paroxetine.
Siltuximab Injection Siltuximab Injection The metabolism of Paroxetine can be increased when combined with Siltuximab.
Albiglutide Injection Albiglutide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Albiglutide.
Eslicarbazepine Eslicarbazepine The risk or severity of adverse effects can be increased when Eslicarbazepine is combined with Paroxetine.
Belinostat Injection Belinostat Injection The metabolism of Paroxetine can be increased when combined with Belinostat.
Idelalisib Idelalisib The metabolism of Idelalisib can be decreased when combined with Paroxetine.
Testosterone Injection Testosterone Injection The metabolism of Testosterone can be decreased when combined with Paroxetine.
Oritavancin Injection Oritavancin Injection The metabolism of Paroxetine can be decreased when combined with Oritavancin.
Empagliflozin Empagliflozin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Empagliflozin.
Vorapaxar Vorapaxar The risk or severity of hemorrhage can be increased when Paroxetine is combined with Vorapaxar.
Hydrocodone Hydrocodone Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Suvorexant Suvorexant Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Dulaglutide Injection Dulaglutide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Dulaglutide.
Edoxaban Edoxaban The risk or severity of hemorrhage can be increased when Paroxetine is combined with Edoxaban.
Peginterferon Beta-1a Injection Peginterferon Beta-1a Injection The metabolism of Paroxetine can be decreased when combined with Peginterferon beta-1a.
Olaparib Olaparib The metabolism of Olaparib can be decreased when combined with Paroxetine.
Methamphetamine Methamphetamine The metabolism of Metamfetamine can be decreased when combined with Paroxetine.
Tasimelteon Tasimelteon The risk or severity of adverse effects can be increased when Tasimelteon is combined with Paroxetine.
Lanreotide Injection Lanreotide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lanreotide.
Pirfenidone Pirfenidone The metabolism of Pirfenidone can be decreased when combined with Paroxetine.
Nintedanib Nintedanib The metabolism of Nintedanib can be decreased when combined with Paroxetine.
Secukinumab Injection Secukinumab Injection The metabolism of Paroxetine can be increased when combined with Secukinumab.
Risperidone Injection Risperidone Injection The serum concentration of Risperidone can be increased when it is combined with Paroxetine.
Palbociclib Palbociclib The metabolism of Palbociclib can be decreased when combined with Paroxetine.
Insulin Human Inhalation Insulin Human Inhalation The metabolism of Paroxetine can be increased when combined with Insulin human.
Lenvatinib Lenvatinib The metabolism of Paroxetine can be decreased when combined with Lenvatinib.
Naloxegol Naloxegol The metabolism of Paroxetine can be decreased when combined with Naloxegol.
Panobinostat Panobinostat The metabolism of Panobinostat can be decreased when combined with Paroxetine.
Haloperidol Injection Haloperidol Injection The risk or severity of CNS depression can be increased when Haloperidol is combined with Paroxetine.
Sonidegib Sonidegib The metabolism of Sonidegib can be decreased when combined with Paroxetine.
Flibanserin Flibanserin The risk or severity of adverse effects can be increased when Paroxetine is combined with Flibanserin.
Rolapitant Rolapitant The metabolism of Rolapitant can be decreased when combined with Paroxetine.
Brexpiprazole Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Paroxetine.
Ziprasidone Injection Ziprasidone Injection The risk or severity of adverse effects can be increased when Ziprasidone is combined with Paroxetine.
Cariprazine Cariprazine The metabolism of Cariprazine can be decreased when combined with Paroxetine.
Eluxadoline Eluxadoline The risk or severity of constipation can be increased when Paroxetine is combined with Eluxadoline.
Insulin Degludec (rDNA Origin) Injection Insulin Degludec (rDNA Origin) Injection The metabolism of Paroxetine can be increased when combined with Insulin degludec.
Cobimetinib Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Paroxetine.
Trabectedin Injection Trabectedin Injection The metabolism of Trabectedin can be decreased when combined with Paroxetine.
Osimertinib Osimertinib The serum concentration of Paroxetine can be decreased when it is combined with Osimertinib.
Alectinib Alectinib The metabolism of Alectinib can be decreased when combined with Paroxetine.
Ixazomib Ixazomib The metabolism of Ixazomib can be decreased when combined with Paroxetine.
Rifapentine Rifapentine The metabolism of Paroxetine can be increased when combined with Rifapentine.
Lesinurad Lesinurad The metabolism of Lesinurad can be decreased when combined with Paroxetine.
Defibrotide Injection Defibrotide Injection The risk or severity of hemorrhage can be increased when Paroxetine is combined with Defibrotide.
Brivaracetam Injection Brivaracetam Injection The risk or severity of adverse effects can be increased when Brivaracetam is combined with Paroxetine.
Venetoclax Venetoclax The metabolism of Venetoclax can be decreased when combined with Paroxetine.
Cobicistat Cobicistat The metabolism of Paroxetine can be decreased when combined with Cobicistat.
Midodrine Midodrine The risk or severity of Tachycardia can be increased when Midodrine is combined with Paroxetine.
Pimavanserin Pimavanserin The risk or severity of adverse effects can be increased when Paroxetine is combined with Pimavanserin.
Obeticholic Acid Obeticholic Acid The metabolism of Paroxetine can be decreased when combined with Obeticholic acid.
Diphenhydramine Injection Diphenhydramine Injection The metabolism of Diphenhydramine can be decreased when combined with Paroxetine.
Rucaparib Rucaparib The metabolism of Rucaparib can be decreased when combined with Paroxetine.
Lixisenatide Injection Lixisenatide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Lixisenatide.
Ribociclib Ribociclib The metabolism of Ribociclib can be decreased when combined with Paroxetine.
Parathyroid Hormone Injection Parathyroid Hormone Injection The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Paroxetine.
Brigatinib Brigatinib The metabolism of Brigatinib can be decreased when combined with Paroxetine.
Doxepin (Insomnia) Doxepin (Insomnia) The metabolism of Doxepin can be decreased when combined with Paroxetine.
Plecanatide Plecanatide The therapeutic efficacy of Plecanatide can be decreased when used in combination with Paroxetine.
Deutetrabenazine Deutetrabenazine The serum concentration of the active metabolites of Deutetrabenazine can be increased when Deutetrabenazine is used in combination with Paroxetine.
Valbenazine Valbenazine The metabolism of Valbenazine can be decreased when combined with Paroxetine.
Safinamide Safinamide Safinamide may increase the serotonergic activities of Paroxetine.
Midostaurin Midostaurin The metabolism of Paroxetine can be decreased when combined with Midostaurin.
Neratinib Neratinib The metabolism of Neratinib can be decreased when combined with Paroxetine.
Abaloparatide Injection Abaloparatide Injection The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Paroxetine.
Enasidenib Enasidenib The metabolism of Enasidenib can be decreased when combined with Paroxetine.
Aprepitant/Fosaprepitant Injection Aprepitant/Fosaprepitant Injection The metabolism of Fosaprepitant can be decreased when combined with Paroxetine.
Copanlisib Injection Copanlisib Injection The metabolism of Copanlisib can be decreased when combined with Paroxetine.
Abemaciclib Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Paroxetine.
Betrixaban Betrixaban The risk or severity of hemorrhage can be increased when Paroxetine is combined with Betrixaban.
Acalabrutinib Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with Paroxetine.
Letermovir Letermovir The metabolism of Letermovir can be decreased when combined with Paroxetine.
Semaglutide Injection Semaglutide Injection The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Semaglutide.
Tetrabenazine Tetrabenazine The metabolism of Tetrabenazine can be decreased when combined with Paroxetine.
Ertugliflozin Ertugliflozin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Ertugliflozin.
Buprenorphine Injection Buprenorphine Injection Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Apalutamide Apalutamide The serum concentration of Paroxetine can be increased when it is combined with Apalutamide.
Baricitinib Baricitinib The metabolism of Baricitinib can be decreased when combined with Paroxetine.
Lofexidine Lofexidine The therapeutic efficacy of Paroxetine can be increased when used in combination with Lofexidine.
Eliglustat Eliglustat The metabolism of Eliglustat can be decreased when combined with Paroxetine.
Encorafenib Encorafenib The metabolism of Encorafenib can be decreased when combined with Paroxetine.
Binimetinib Binimetinib The metabolism of Binimetinib can be decreased when combined with Paroxetine.
Ivosidenib Ivosidenib The metabolism of Ivosidenib can be decreased when combined with Paroxetine.
Elagolix Elagolix The metabolism of Elagolix can be decreased when combined with Paroxetine.
Tafenoquine Tafenoquine The metabolism of Tafenoquine can be decreased when combined with Paroxetine.
Cannabidiol Cannabidiol The risk or severity of adverse effects can be increased when Cannabidiol is combined with Paroxetine.
Dacomitinib Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Paroxetine.
Duvelisib Duvelisib The metabolism of Duvelisib can be decreased when combined with Paroxetine.
Stiripentol Stiripentol The metabolism of Paroxetine can be decreased when combined with Stiripentol.
Gilteritinib Gilteritinib The therapeutic efficacy of Paroxetine can be decreased when used in combination with Gilteritinib.
Lorlatinib Lorlatinib The metabolism of Lorlatinib can be decreased when combined with Paroxetine.
Paclitaxel (with albumin) Injection Paclitaxel (with albumin) Injection The metabolism of Paclitaxel can be decreased when combined with Paroxetine.
Rifamycin Rifamycin The metabolism of Rifamycin can be increased when combined with Paroxetine.
Prucalopride Prucalopride The metabolism of Prucalopride can be decreased when combined with Paroxetine.
Magnesium Citrate Magnesium Citrate The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Paroxetine.
Emapalumab-lzsg Injection Emapalumab-lzsg Injection The metabolism of Paroxetine can be increased when combined with Emapalumab.
Siponimod Siponimod The metabolism of Siponimod can be decreased when combined with Paroxetine.
Acyclovir Ophthalmic Acyclovir Ophthalmic The metabolism of Acyclovir can be decreased when combined with Paroxetine.
Caplacizumab-yhdp Injection Caplacizumab-yhdp Injection The risk or severity of hemorrhage can be increased when Paroxetine is combined with Caplacizumab.
Erdafitinib Erdafitinib The metabolism of Erdafitinib can be decreased when combined with Paroxetine.
Esomeprazole Injection Esomeprazole Injection The metabolism of Paroxetine can be decreased when combined with Esomeprazole.
Alpelisib Alpelisib The metabolism of Alpelisib can be decreased when combined with Paroxetine.
Brexanolone Injection Brexanolone Injection The risk or severity of adverse effects can be increased when Brexanolone is combined with Paroxetine.
Solriamfetol Solriamfetol The risk or severity of Tachycardia can be increased when Solriamfetol is combined with Paroxetine.
Triclabendazole Triclabendazole The metabolism of Triclabendazole can be decreased when combined with Paroxetine.
Entrectinib Entrectinib The metabolism of Entrectinib can be decreased when combined with Paroxetine.
Pexidartinib Pexidartinib The metabolism of Pexidartinib can be decreased when combined with Paroxetine.
Istradefylline Istradefylline The metabolism of Istradefylline can be decreased when combined with Paroxetine.
Pitolisant Pitolisant The serum concentration of Pitolisant can be increased when it is combined with Paroxetine.
Fedratinib Fedratinib The metabolism of Fedratinib can be decreased when combined with Paroxetine.
Lefamulin Lefamulin The metabolism of Lefamulin can be decreased when combined with Paroxetine.
Phenytoin Injection Phenytoin Injection The serum concentration of Phenytoin can be decreased when it is combined with Paroxetine.
Fosphenytoin Injection Fosphenytoin Injection The serum concentration of Fosphenytoin can be decreased when it is combined with Paroxetine.
Zanubrutinib Zanubrutinib The metabolism of Zanubrutinib can be decreased when combined with Paroxetine.
Voxelotor Voxelotor The serum concentration of Voxelotor can be increased when it is combined with Paroxetine.
Avapritinib Avapritinib The metabolism of Avapritinib can be decreased when combined with Paroxetine.
Lumateperone Lumateperone The risk or severity of adverse effects can be increased when Lumateperone is combined with Paroxetine.
Lasmiditan Lasmiditan The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Paroxetine.
Tazemetostat Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Paroxetine.
Cenobamate Cenobamate The serum concentration of Cenobamate can be decreased when it is combined with Paroxetine.
Selumetinib Selumetinib The metabolism of Selumetinib can be decreased when combined with Paroxetine.
Tucatinib Tucatinib The metabolism of Tucatinib can be decreased when combined with Paroxetine.
Selpercatinib Selpercatinib The serum concentration of Selpercatinib can be increased when it is combined with Paroxetine.
Capmatinib Capmatinib The serum concentration of Capmatinib can be increased when it is combined with Paroxetine.
Lemborexant Lemborexant The serum concentration of Lemborexant can be increased when it is combined with Paroxetine.
Fenfluramine Fenfluramine The risk or severity of serotonin syndrome can be increased when Fenfluramine is combined with Paroxetine.
Octreotide Octreotide The risk or severity of hypoglycemia can be increased when Octreotide is combined with Paroxetine.
Satralizumab-mwge Injection Satralizumab-mwge Injection The serum concentration of Paroxetine can be decreased when it is combined with Satralizumab.
Progestin-Only (drospirenone) Oral Contraceptives Progestin-Only (drospirenone) Oral Contraceptives The metabolism of Drospirenone can be decreased when combined with Paroxetine.
Viloxazine Viloxazine The risk or severity of adverse effects can be increased when Paroxetine is combined with Viloxazine.
Theophylline Theophylline The serum concentration of Theophylline can be increased when it is combined with Paroxetine.
Fenoprofen Fenoprofen The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Fenoprofen.
Indomethacin Indomethacin The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Indomethacin.
Mefenamic Acid Mefenamic Acid The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mefenamic acid.
Naproxen Naproxen The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Naproxen.
Tolmetin Tolmetin The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Tolmetin.
Sulindac Sulindac The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Sulindac.
Trazodone Trazodone The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Trazodone.
Hydroxyurea Hydroxyurea The metabolism of Paroxetine can be decreased when combined with Hydroxyurea.
Phenobarbital Phenobarbital The metabolism of Phenobarbital can be decreased when combined with Paroxetine.
Metaxalone Metaxalone The risk or severity of adverse effects can be increased when Metaxalone is combined with Paroxetine.
Methotrexate Injection Methotrexate Injection The metabolism of Methotrexate can be decreased when combined with Paroxetine.
Levorphanol Levorphanol The risk or severity of serotonin syndrome can be increased when Levorphanol is combined with Paroxetine.
Primidone Primidone The metabolism of Paroxetine can be increased when combined with Primidone.
Methsuximide Methsuximide The risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.
Diethylpropion Diethylpropion The risk or severity of adverse effects can be increased when Paroxetine is combined with Diethylpropion.
Chlorpromazine Chlorpromazine The metabolism of Paroxetine can be decreased when combined with Chlorpromazine.
Diazepam Diazepam The risk or severity of adverse effects can be increased when Paroxetine is combined with Diazepam.
Oxazepam Oxazepam The risk or severity of adverse effects can be increased when Paroxetine is combined with Oxazepam.
Flurazepam Flurazepam The risk or severity of adverse effects can be increased when Flurazepam is combined with Paroxetine.
Clorazepate Clorazepate The risk or severity of adverse effects can be increased when Clorazepic acid is combined with Paroxetine.
Lorazepam Lorazepam The risk or severity of adverse effects can be increased when Lorazepam is combined with Paroxetine.
Carmustine Carmustine The metabolism of Paroxetine can be decreased when combined with Carmustine.
Amantadine Amantadine The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Amantadine.
Codeine Codeine The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Codeine.
Meprobamate Meprobamate The risk or severity of adverse effects can be increased when Meprobamate is combined with Paroxetine.
Chlordiazepoxide Chlordiazepoxide The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Paroxetine.
Bromocriptine Bromocriptine The risk or severity of adverse effects can be increased when Bromocriptine is combined with Paroxetine.
Metaproterenol Metaproterenol The risk or severity of Tachycardia can be increased when Paroxetine is combined with Orciprenaline.
Tranylcypromine Tranylcypromine Paroxetine may increase the serotonergic activities of Tranylcypromine.
Phenelzine Phenelzine Paroxetine may increase the serotonergic activities of Phenelzine.
Procarbazine Procarbazine Procarbazine may increase the serotonergic activities of Paroxetine.
Ergoloid Mesylates Ergoloid Mesylates The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Paroxetine.
Minocycline Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Prochlorperazine Prochlorperazine The metabolism of Paroxetine can be decreased when combined with Prochlorperazine.
Thioridazine Thioridazine Paroxetine may increase the QTc-prolonging activities of Thioridazine.
Trifluoperazine Trifluoperazine The risk or severity of adverse effects can be increased when Paroxetine is combined with Trifluoperazine.
Dapsone Dapsone The metabolism of Dapsone can be decreased when combined with Paroxetine.
Sulfadiazine Sulfadiazine The risk or severity of hypoglycemia can be increased when Sulfadiazine is combined with Paroxetine.
Oxycodone Oxycodone The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Oxycodone.
Methadone Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Paroxetine.
Oxybutynin Oxybutynin The metabolism of Paroxetine can be decreased when combined with Oxybutynin.
Benztropine Benztropine The metabolism of Benzatropine can be decreased when combined with Paroxetine.
Maprotiline Maprotiline The metabolism of Maprotiline can be decreased when combined with Paroxetine.
Ibuprofen Ibuprofen The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ibuprofen.
Trihexyphenidyl Trihexyphenidyl Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.
Orphenadrine Orphenadrine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Perphenazine Perphenazine The metabolism of Perphenazine can be decreased when combined with Paroxetine.
Azathioprine Azathioprine The metabolism of Azathioprine can be decreased when combined with Paroxetine.
Fluphenazine Fluphenazine The risk or severity of adverse effects can be increased when Fluphenazine is combined with Paroxetine.
Phentermine Phentermine The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Paroxetine.
Amoxapine Amoxapine The metabolism of Paroxetine can be decreased when combined with Amoxapine.
Sulfasalazine Sulfasalazine The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Sulfasalazine.
Doxorubicin Doxorubicin The metabolism of Paroxetine can be decreased when combined with Doxorubicin.
Mechlorethamine Mechlorethamine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Mechlorethamine.
Pyridostigmine Pyridostigmine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Pyridostigmine.
Carbamazepine Carbamazepine The metabolism of Paroxetine can be decreased when combined with Carbamazepine.
Molindone Molindone The risk or severity of adverse effects can be increased when Paroxetine is combined with Molindone.
Clonidine Clonidine The risk or severity of sedation can be increased when Clonidine is combined with Paroxetine.
Cimetidine Cimetidine The serum concentration of Paroxetine can be increased when it is combined with Cimetidine.
Warfarin Warfarin The risk or severity of bleeding can be increased when Paroxetine is combined with Warfarin.
Clonazepam Clonazepam The risk or severity of adverse effects can be increased when Clonazepam is combined with Paroxetine.
Loperamide Loperamide The metabolism of Loperamide can be decreased when combined with Paroxetine.
Promethazine Promethazine The metabolism of Promethazine can be decreased when combined with Paroxetine.
Meclofenamate Meclofenamate The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Meclofenamic acid.
Griseofulvin Griseofulvin The metabolism of Paroxetine can be increased when combined with Griseofulvin.
Loxapine Loxapine The risk or severity of adverse effects can be increased when Loxapine is combined with Paroxetine.
Chloroquine Chloroquine The metabolism of Chloroquine can be decreased when combined with Paroxetine.
Quinine Quinine The metabolism of Quinine can be decreased when combined with Paroxetine.
Ethosuximide Ethosuximide The risk or severity of adverse effects can be increased when Ethosuximide is combined with Paroxetine.
Triamterene Triamterene The metabolism of Paroxetine can be decreased when combined with Triamterene.
Lactulose Lactulose The therapeutic efficacy of Lactulose can be decreased when used in combination with Paroxetine.
Sulfinpyrazone Sulfinpyrazone The risk or severity of hemorrhage can be increased when Paroxetine is combined with Sulfinpyrazone.
Chlorothiazide Chlorothiazide The risk or severity of hyponatremia can be increased when Paroxetine is combined with Chlorothiazide.
Chlorthalidone Chlorthalidone The risk or severity of hyponatremia can be increased when Paroxetine is combined with Chlorthalidone.
Metolazone Metolazone The risk or severity of hyponatremia can be increased when Paroxetine is combined with Metolazone.
Clindamycin Injection Clindamycin Injection The metabolism of Clindamycin can be decreased when combined with Paroxetine.
Secobarbital Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Paroxetine.
Desipramine Desipramine The metabolism of Desipramine can be decreased when combined with Paroxetine.
Amitriptyline Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Paroxetine.
Imipramine Imipramine The metabolism of Paroxetine can be decreased when combined with Imipramine.
Probenecid Probenecid The metabolism of Paroxetine can be decreased when combined with Probenecid.
Quinidine Quinidine The metabolism of Quinidine can be decreased when combined with Paroxetine.
Procainamide Procainamide The metabolism of Procainamide can be decreased when combined with Paroxetine.
Isoniazid Isoniazid The metabolism of Paroxetine can be decreased when combined with Isoniazid.
Rifampin Rifampin The metabolism of Paroxetine can be increased when combined with Rifampicin.
Disopyramide Disopyramide Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.
Valproic Acid Valproic Acid The risk or severity of adverse effects can be increased when Valproic acid is combined with Paroxetine.
Tamoxifen Tamoxifen The therapeutic efficacy of Tamoxifen can be decreased when used in combination with Paroxetine.
Butabarbital Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Paroxetine.
Levothyroxine Levothyroxine The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Paroxetine.
Liothyronine Liothyronine The therapeutic efficacy of Liothyronine can be decreased when used in combination with Paroxetine.
Methimazole Methimazole The metabolism of Paroxetine can be decreased when combined with Methimazole.
Propylthiouracil Propylthiouracil The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Paroxetine.
Chlorpropamide Chlorpropamide The metabolism of Chlorpropamide can be decreased when combined with Paroxetine.
Glucagon Injection Glucagon Injection Paroxetine may increase the gastrointestinal motility reducing activities of Glucagon.
Tolbutamide Tolbutamide The metabolism of Tolbutamide can be decreased when combined with Paroxetine.
Tolazamide Tolazamide The metabolism of Tolazamide can be decreased when combined with Paroxetine.
Dextromethorphan Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Paroxetine.
Cyclobenzaprine Cyclobenzaprine The risk or severity of CNS depression can be increased when Paroxetine is combined with Cyclobenzaprine.
Niacin Niacin The metabolism of Paroxetine can be decreased when combined with Niacin.
Baclofen Baclofen The risk or severity of adverse effects can be increased when Baclofen is combined with Paroxetine.
Doxylamine Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Cyproheptadine Cyproheptadine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Cyproheptadine.
Clemastine Clemastine The risk or severity of adverse effects can be increased when Paroxetine is combined with Clemastine.
Chlorpheniramine Chlorpheniramine The metabolism of Chlorpheniramine can be decreased when combined with Paroxetine.
Brompheniramine Brompheniramine The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Paroxetine.
Meclizine Meclizine The metabolism of Meclizine can be decreased when combined with Paroxetine.
Methyclothiazide Methyclothiazide The risk or severity of hyponatremia can be increased when Paroxetine is combined with Methyclothiazide.
Hydrochlorothiazide Hydrochlorothiazide The risk or severity of hyponatremia can be increased when Paroxetine is combined with Hydrochlorothiazide.
Dantrolene Dantrolene The risk or severity of adverse effects can be increased when Dantrolene is combined with Paroxetine.
Chlorzoxazone Chlorzoxazone The metabolism of Chlorzoxazone can be decreased when combined with Paroxetine.
Carisoprodol Carisoprodol The risk or severity of adverse effects can be increased when Carisoprodol is combined with Paroxetine.
Methocarbamol Methocarbamol The risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.
Pseudoephedrine Pseudoephedrine The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Pseudoephedrine.
Nortriptyline Nortriptyline The metabolism of Paroxetine can be decreased when combined with Nortriptyline.
Nadolol Nadolol The metabolism of Nadolol can be decreased when combined with Paroxetine.
Butorphanol Injection Butorphanol Injection The risk or severity of serotonin syndrome can be increased when Butorphanol is combined with Paroxetine.
Nalbuphine Injection Nalbuphine Injection The risk or severity of serotonin syndrome can be increased when Nalbuphine is combined with Paroxetine.
Trimethobenzamide Trimethobenzamide The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Paroxetine.
Flavoxate Flavoxate Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.
Fluorouracil Injection Fluorouracil Injection The metabolism of Paroxetine can be decreased when combined with Fluorouracil.
Colchicine Colchicine The metabolism of Colchicine can be decreased when combined with Paroxetine.
Cephalexin Cephalexin The metabolism of Cephalexin can be decreased when combined with Paroxetine.
Dacarbazine Dacarbazine The metabolism of Dacarbazine can be decreased when combined with Paroxetine.
Acetazolamide Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Paroxetine.
Calcitonin Salmon Injection Calcitonin Salmon Injection The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Paroxetine.
Ketoconazole Ketoconazole The metabolism of Paroxetine can be decreased when combined with Ketoconazole.
Pyrantel Pyrantel The risk or severity of adverse effects can be increased when Pyrantel is combined with Paroxetine.
Thiotepa Injection Thiotepa Injection The metabolism of Paroxetine can be decreased when combined with Thiotepa.
Vincristine Injection Vincristine Injection The metabolism of Vincristine can be decreased when combined with Paroxetine.
Dipyridamole Dipyridamole The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dipyridamole.
Isoxsuprine Isoxsuprine The risk or severity of Tachycardia can be increased when Paroxetine is combined with Isoxsuprine.
Vinblastine Vinblastine The metabolism of Paroxetine can be decreased when combined with Vinblastine.
Metoprolol Metoprolol The metabolism of Metoprolol can be decreased when combined with Paroxetine.
Hydroxyzine Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paroxetine.
Thiothixene Thiothixene The risk or severity of adverse effects can be increased when Paroxetine is combined with Thiothixene.
Aspirin Aspirin The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Acetylsalicylic acid.
Salsalate Salsalate The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Salsalate.
Alprazolam Alprazolam The metabolism of Alprazolam can be decreased when combined with Paroxetine.
Temazepam Temazepam The risk or severity of adverse effects can be increased when Temazepam is combined with Paroxetine.
Triazolam Triazolam The risk or severity of adverse effects can be increased when Triazolam is combined with Paroxetine.
Dicyclomine Dicyclomine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.
Hyoscyamine Hyoscyamine Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.
Propantheline Propantheline Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.
Trimethoprim Trimethoprim The metabolism of Trimethoprim can be decreased when combined with Paroxetine.
Diltiazem Diltiazem The metabolism of Diltiazem can be decreased when combined with Paroxetine.
Nifedipine Nifedipine The metabolism of Nifedipine can be decreased when combined with Paroxetine.
Timolol Timolol The metabolism of Timolol can be decreased when combined with Paroxetine.
Verapamil Verapamil The metabolism of Verapamil can be decreased when combined with Paroxetine.
Atenolol Atenolol The metabolism of Atenolol can be decreased when combined with Paroxetine.
Pindolol Pindolol The metabolism of Pindolol can be decreased when combined with Paroxetine.
Cisplatin Injection Cisplatin Injection The therapeutic efficacy of Paroxetine can be decreased when used in combination with Cisplatin.
Diflunisal Diflunisal The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Diflunisal.
Piroxicam Piroxicam The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Piroxicam.
Streptozocin Streptozocin The metabolism of Paroxetine can be increased when combined with Streptozocin.
Etoposide Etoposide The metabolism of Etoposide can be decreased when combined with Paroxetine.
Glyburide Glyburide The metabolism of Glyburide can be decreased when combined with Paroxetine.
Glipizide Glipizide The metabolism of Glipizide can be decreased when combined with Paroxetine.
Indapamide Indapamide The risk or severity of hyponatremia can be increased when Paroxetine is combined with Indapamide.
Nafcillin Injection Nafcillin Injection The metabolism of Paroxetine can be increased when combined with Nafcillin.
Pentoxifylline Pentoxifylline The risk or severity of hemorrhage can be increased when Paroxetine is combined with Pentoxifylline.
Pentamidine Injection Pentamidine Injection The metabolism of Pentamidine can be decreased when combined with Paroxetine.
Labetalol Labetalol The metabolism of Labetalol can be decreased when combined with Paroxetine.
Gemfibrozil Gemfibrozil The metabolism of Gemfibrozil can be decreased when combined with Paroxetine.
Guanabenz Guanabenz The metabolism of Paroxetine can be decreased when combined with Guanabenz.
Ketoprofen Ketoprofen The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Ketoprofen.
Pimozide Pimozide The risk or severity of QTc prolongation can be increased when Paroxetine is combined with Pimozide.
Flurbiprofen Flurbiprofen The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Flurbiprofen.
Amiodarone Amiodarone The metabolism of Amiodarone can be decreased when combined with Paroxetine.
Buspirone Buspirone The metabolism of Buspirone can be decreased when combined with Paroxetine.
Lovastatin Lovastatin The metabolism of Lovastatin can be decreased when combined with Paroxetine.
Ciprofloxacin Ciprofloxacin The metabolism of Paroxetine can be decreased when combined with Ciprofloxacin.
Mesalamine Mesalamine The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Mesalazine.
Diclofenac Diclofenac The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Diclofenac.
Fluoxetine Fluoxetine The serum concentration of Paroxetine can be increased when it is combined with Fluoxetine.
Interferon Alfa-2b Injection Interferon Alfa-2b Injection The metabolism of Paroxetine can be decreased when combined with Interferon alfa-2b.
Clozapine Clozapine The metabolism of Paroxetine can be decreased when combined with Clozapine.
Estazolam Estazolam The risk or severity of adverse effects can be increased when Paroxetine is combined with Estazolam.
Idarubicin Idarubicin The metabolism of Idarubicin can be decreased when combined with Paroxetine.
Ofloxacin Ofloxacin The metabolism of Paroxetine can be decreased when combined with Ofloxacin.
Etodolac Etodolac The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Etodolac.
Felodipine Felodipine The metabolism of Paroxetine can be decreased when combined with Felodipine.
Nabumetone Nabumetone The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Nabumetone.
Pravastatin Pravastatin The risk or severity of increased glucose can be increased when Pravastatin is combined with Paroxetine.
Simvastatin Simvastatin The metabolism of Simvastatin can be decreased when combined with Paroxetine.
Teniposide Injection Teniposide Injection The metabolism of Teniposide can be decreased when combined with Paroxetine.
Oxaprozin Oxaprozin The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Oxaprozin.
Rifabutin Rifabutin The metabolism of Paroxetine can be increased when combined with Rifabutin.
Sotalol Sotalol The metabolism of Sotalol can be decreased when combined with Paroxetine.
Bisoprolol Bisoprolol The serum concentration of Bisoprolol can be increased when it is combined with Paroxetine.
Zolpidem Zolpidem Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Doxazosin Doxazosin The metabolism of Doxazosin can be decreased when combined with Paroxetine.
Omeprazole Omeprazole The metabolism of Omeprazole can be decreased when combined with Paroxetine.
Cisapride Cisapride The metabolism of Paroxetine can be decreased when combined with Cisapride.
Gabapentin Gabapentin The risk or severity of adverse effects can be increased when Paroxetine is combined with Gabapentin.
Fluvastatin Fluvastatin The metabolism of Fluvastatin can be decreased when combined with Paroxetine.
Venlafaxine Venlafaxine The metabolism of Paroxetine can be decreased when combined with Venlafaxine.
Nizatidine Nizatidine The therapeutic efficacy of Paroxetine can be decreased when used in combination with Nizatidine.
Famciclovir Famciclovir The metabolism of Famciclovir can be decreased when combined with Paroxetine.
Fluvoxamine Fluvoxamine The metabolism of Paroxetine can be decreased when combined with Fluvoxamine.
Nefazodone Nefazodone The metabolism of Nefazodone can be decreased when combined with Paroxetine.
Lamotrigine Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Paroxetine.
Losartan Losartan The metabolism of Losartan can be decreased when combined with Paroxetine.
Tramadol Tramadol The risk or severity of serotonin syndrome can be increased when Paroxetine is combined with Tramadol.
Vinorelbine Injection Vinorelbine Injection The metabolism of Paroxetine can be decreased when combined with Vinorelbine.
Lansoprazole Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Paroxetine.
Ifosfamide Injection Ifosfamide Injection The metabolism of Ifosfamide can be decreased when combined with Paroxetine.
Nicardipine Nicardipine The metabolism of Paroxetine can be decreased when combined with Nicardipine.
Bupropion Bupropion The risk or severity of adverse effects can be increased when Bupropion is combined with Paroxetine.
Ticlopidine Ticlopidine The metabolism of Ticlopidine can be decreased when combined with Paroxetine.
Saquinavir Saquinavir The metabolism of Paroxetine can be decreased when combined with Saquinavir.
Metformin Metformin The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Metformin.
Dalteparin Injection Dalteparin Injection The risk or severity of hemorrhage can be increased when Paroxetine is combined with Dalteparin.
Riluzole Riluzole The risk or severity of adverse effects can be increased when Riluzole is combined with Paroxetine.
Acarbose Acarbose The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Acarbose.
Glimepiride Glimepiride The metabolism of Glimepiride can be decreased when combined with Paroxetine.
Ritonavir Ritonavir The serum concentration of Paroxetine can be increased when it is combined with Ritonavir.
Docetaxel Injection Docetaxel Injection The metabolism of Docetaxel can be decreased when combined with Paroxetine.
Clomipramine Clomipramine The metabolism of Paroxetine can be decreased when combined with Clomipramine.
Zafirlukast Zafirlukast The metabolism of Paroxetine can be decreased when combined with Zafirlukast.
Mirtazapine Mirtazapine Paroxetine may increase the serotonergic activities of Mirtazapine.
Topiramate Topiramate The risk or severity of hyperthermia and oligohydrosis can be increased when Paroxetine is combined with Topiramate.
Zileuton Zileuton The metabolism of Zileuton can be decreased when combined with Paroxetine.
Valsartan Valsartan The metabolism of Paroxetine can be decreased when combined with Valsartan.
Insulin Lispro Injection Insulin Lispro Injection The metabolism of Paroxetine can be increased when combined with Insulin lispro.
Pramipexole Pramipexole Paroxetine may increase the sedative activities of Pramipexole.
Donepezil Donepezil The therapeutic efficacy of Paroxetine can be decreased when used in combination with Donepezil.
Nelfinavir Nelfinavir The metabolism of Nelfinavir can be decreased when combined with Paroxetine.
Azithromycin Azithromycin The metabolism of Azithromycin can be decreased when combined with Paroxetine.
Loratadine Loratadine Paroxetine may increase the anticholinergic activities of Loratadine.
Carvedilol Carvedilol The metabolism of Carvedilol can be decreased when combined with Paroxetine.
Nilutamide Nilutamide The metabolism of Paroxetine can be decreased when combined with Nilutamide.
Flutamide Flutamide The metabolism of Paroxetine can be decreased when combined with Flutamide.
Selegiline Selegiline Paroxetine may increase the serotonergic activities of Selegiline.
Bicalutamide Bicalutamide The metabolism of Paroxetine can be decreased when combined with Bicalutamide.
Sertraline Sertraline The metabolism of Sertraline can be decreased when combined with Paroxetine.
Propafenone Propafenone The metabolism of Propafenone can be decreased when combined with Paroxetine.
Letrozole Letrozole The metabolism of Paroxetine can be decreased when combined with Letrozole.
Irbesartan Irbesartan The metabolism of Irbesartan can be decreased when combined with Paroxetine.
Tamsulosin Tamsulosin The metabolism of Tamsulosin can be decreased when combined with Paroxetine.
Ropinirole Ropinirole Paroxetine may increase the sedative activities of Ropinirole.
Quetiapine Quetiapine The metabolism of Quetiapine can be decreased when combined with Paroxetine.
Cetirizine Cetirizine The risk or severity of adverse effects can be increased when Cetirizine is combined with Paroxetine.
Tolcapone Tolcapone The risk or severity of adverse effects can be increased when Tolcapone is combined with Paroxetine.
Citalopram Citalopram Citalopram may increase the QTc-prolonging activities of Paroxetine.
Capecitabine Capecitabine The metabolism of Capecitabine can be decreased when combined with Paroxetine.
Efavirenz Efavirenz The risk or severity of adverse effects can be increased when Efavirenz is combined with Paroxetine.
Sildenafil Sildenafil The metabolism of Sildenafil can be decreased when combined with Paroxetine.
Pioglitazone Pioglitazone The risk or severity of hypoglycemia can be increased when Paroxetine is combined with Pioglitazone.
Celecoxib Celecoxib The risk or severity of bleeding can be increased when Celecoxib is combined with Paroxetine.
Rosiglitazone Rosiglitazone The metabolism of Paroxetine can be decreased when combined with Rosiglitazone.
Tolterodine Tolterodine The metabolism of Tolterodine can be decreased when combined with Paroxetine.
Thalidomide Thalidomide Paroxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Balsalazide Balsalazide The risk or severity of gastrointestinal bleeding can be increased when Paroxetine is combined with Balsalazide.
Nateglinide Nateglinide The metabolism of Nateglinide can be decreased when combined with Paroxetine.
Galantamine Galantamine The metabolism of Paroxetine can be decreased when combined with Galantamine.
Levetiracetam Levetiracetam The risk or severity of adverse effects can be increased when Levetiracetam is combined with Paroxetine.
Rabeprazole Rabeprazole The metabolism of Rabeprazole can be decreased when combined with Paroxetine.
Terbinafine Terbinafine The metabolism of Paroxetine can be decreased when combined with Terbinafine.

Content provided by: AHFS® Patient Medication Information™. © Copyright, 2021. The American Society of Health-System Pharmacists